Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sharper eye on amyloid: could quantitative scans revolutionize cardiac monitoring?

NCT ID NCT04849754

Diagnosis Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether a quantitative analysis of bone scintigraphy (SUVmax) can better track amyloid burden in the hearts of patients with transthyretin cardiac amyloidosis who are being treated with tafamidis. The current Perugini score is limited in assessing disease severity and prognosis. The study will enroll 30 adults with this condition to see if this new measurement method provides a more precise tool for monitoring disease progression and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bone scintigraphy (a diagnostic imaging test using a radioactive tracer to measure amyloid burden in the heart)
What this could lead to
If successful, this could provide a more precise way to monitor disease progression and response to tafamidis treatment in cardiac amyloidosis patients.
What could go wrong
This is a small, early-stage study (30 participants) and the quantitative method is still experimental. It may not prove more useful than existing scoring systems, and results may not generalize to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient, male or female, over 18 years of age * Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * Patient with signed consent Exclusion Criteria: * Patients with systemic AL amyloidosis * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac amyloidosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital privé Le Bois

    RECRUITING

    Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.